Director/PDMR Shareholding

RNS Number : 5246D

GlaxoSmithKline PLC

19 February 2020

 

GlaxoSmithKline plc   (the ' Company ')

Transaction notification

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Ms D Waterhouse
b)	Position/status	CEO of ViiV Healthcare
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Following the vesting on 16 February 2020 of 25% of an award made on 16 February 2015 under the GlaxoSmithKline Deferred Investment Award programme, Ms Waterhouse will receive a cash payment of £240,634.43 less applicable tax withholding in respect of 14,421.337 notional Ordinary Shares.
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£16.686	14,421.337
d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2020-02-16
f)	Place of the transaction	N/A

 

END

 

 

DSHDKLFFBLLLBBL